NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Optimi Health Corp. (OPTH) Stock Analysis

Optimi Health Corp. (OPTH) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

OPTH

$3.53

+$0.17 (+5.06%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare OPTH with… →

OPTH Key Statistics

As of Oct 21, 2026
Trading
Open
$3.49
Previous Close
$3.36
Day's Range
3.27–3.58
52-Week Range
3.04–6.40
Volume
18.79K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.58
Valuation
Market Cap
$20.21M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
115.06
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.56
Financials (FY)
Revenue (FY)
$426.30K+9.35%
Net Income (FY)
−$3.71M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
5.73M
Dividend and dates
Avg Volume
39.24K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

Optimi Health Corp. (OPTH) has a market capitalization of $20.21M.

In fiscal 2025, OPTH reported revenue of $426.30K.

OPTH Revenue and Earnings by Fiscal Year

FY ends September
Fiscal yearRevenueNet incomeNet margin
2025$426.30K−$3.71M−870.8%
2024$389.85K−$6.04M−1,548.3%
2023$181.09K−$5.19M−2,868.5%
2022$80.72K−$7.35M−9,106.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$426.30K−$68.13K−$4.61M−$3.71M−870.8%
2024$389.85K$270.91K−$5.61M−$6.04M−1,548.3%
2023$181.09K$200.23K−$5.27M−$5.19M−2,868.5%
2022$80.72K$53.92K−$7.39M−$7.35M−9,106.9%

Annual figures as reported, in the company's reporting currency. As of September 30, 2025.

OPTH Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricOPTHDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio115.062.1054.8x the median

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 16 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Optimi Health Corp. (OPTH) at $20.21M. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector.

The 52-week range on file runs from $3.04 to $6.40. The most recent close on file for OPTH is $3.53, dated October 21, 2026. That is +$0.17 (+5.06%) against the previous close. The latest close sits 16.12% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $426.30K. That is +9.35% against the prior fiscal year, when revenue was $389.85K. The same year closed with a net loss of $3.71M. Earnings per share on a trailing basis come to −1.56.

Across the 4 fiscal years on file, revenue moves from $80.72K in 2022 to $426.30K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 115.06. On price-to-sales that is 54.8 times the Drug Manufacturers - Specialty & Generic median of 2.1. The medians here are taken across 97 Drug Manufacturers - Specialty & Generic companies that report the metric.

The reported beta is 1.58.

Growth & Income

The record shows no dividend for OPTH.

So far in 2026 the total return is −41.94%.

Peer Comparison

Optimi Health Corp. (OPTH) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Optimi Health Corp. OPTH $20.21M —
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Optimi Health Corp. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Optimi Health Corp.

Optimi Health Corp. operates as a pharmaceutical and nutraceutical drug manufacturing company in Canada. The company manufactures controlled substances including finished MDMA and psilocybin drug products, supplying them directly to authorized clinics, pharmacies, clinical trials, and partners. The company produces and supplies MDMA, natural psilocybin, psilocin, other psychedelic substances, and functional mushrooms derived from botanical sources for health and wellness markets. The company also engages in farming, processing, and distribution of raw mushroom biomass, mushroom extracts, manufacturing of drug products, and mushroom supplements. It sells its products through Amazon marketplace and distributors/brokers, as well as online. Optimi Health Corp. was incorporated in 2020 and is based in Princeton, Canada.

Visit website →